calcitonin and Jaw-Diseases

The aim of this prospective study was to evaluate the outcome of treatment of a group of 17 patients with central giant cell granuloma (CGCG) who were treated in our clinic.. A group of 17 patients with CGCG were treated in the Clinic of Oral and Maxillofacial Surgery of the "G. Papanikolaou" hospital in Thessaloniki. The age range was from 7 to 60 years. Eight patients were male and 9 patients were female. Because most of our patients (11) were less than 30 years old, the aim of the treatment was to eradicate the lesions without functional problems. All of the patients were treated by excision via curettage without a continuity defect and peripheral osteotomy. For 2 patients, the treatment was continued (after the first recurrence) with salmon calcitonin.. The follow-ups ranged from 1 to 15 years. All of the patients were free of the disease, without features of recurrence and without functional or aesthetic problems.. Surgery has usually been considered to be the best method of treatment for CGCG. Most authors have proposed conservative surgical procedures (excision via curettage), especially for young patients. For aggressive lesions, supplementary treatment with calcitonin would provide good results.

Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitonin; Child; Curettage; Female; Follow-Up Studies; Granuloma, Giant Cell; Humans; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Osteotomy; Young Adult

The successful therapeutic use of calcitonin in patients with a central giant cell granuloma has been shown in several case reports. In a prospective, randomized, double-blinded, placebo-controlled clinical trial, 14 patients with a histologically confirmed central giant cell granuloma and normal calcium and parathyroid hormone serum levels were studied over 2 years. Patients were treated with intranasally administered salmon calcitonin (200 IU/day) or a placebo once a day. The placebo-controlled period was 3 months, after which all patients were treated with calcitonin for 1 year. Treatment response was assessed at the end of the placebo-controlled study phase (3 months), at the end of therapy (15 months' timepoint with patients being on calcitonin treatment for either 12 or 15 months) and at 6 months' follow-up. The chi(2)-test was used to compare the proportion of patients with a tumour reduction >/=10% of the pretreatment measurement between the 2 populations at the 3 timepoints: no differences were observed between the placebo group and the calcitonin group. At the 6-month follow-up timepoint, tumour volume had decreased by >/=10% in a total of 7 patients with a 37.9% (95% CI 31.3-44.5%) mean volume reduction in this subgroup. Complete remission was not observed.

Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitonin; Chi-Square Distribution; Child; Double-Blind Method; Female; Granuloma, Giant Cell; Humans; Jaw Diseases; Male; Middle Aged; Prospective Studies; Radiography

This paper reports four cases of central giant cell granuloma (CGCG) treated with calcitonin, attesting the efficacy and safety of its use as the chosen therapy for large CGCG. Four patients presenting CGCG treated with calcitonin were included in this study. Salmon calcitonin was administered for 6-28 months. It was observed determination of clear lesion limits for surgery, reduction and limitation of lesions. In aggressive cases, the calcitonin therapy was an excellent option, since it does not harm the patient, and a far less aggressive, complementary surgery may be performed in certain cases, avoiding life-long sequelae.

Topics: Adolescent; Adult; Bone Density Conservation Agents; Calcitonin; Child; Female; Granuloma, Giant Cell; Humans; Jaw Diseases; Male; Radiography